Bovilis IBR marker Live

Authorised

- Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated

Product identification

Medicine name:
Bovilis IBR marker Live

Active substance:
Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated

Target species:
Cattle

Route of administration:
Nasal use
Intramuscular use

Product details

Active substance and strength:
Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
5.70 log10 50% tissue culture infectious dose / 2.00 millilitre(s)

Pharmaceutical form:
Lyophilisate for suspension for injection

Withdrawal period by route of administration:

Nasal use:

- **Cattle**
  - Milk. no withdrawal period zero days
  - Meat and offal. no withdrawal period zero days

Intramuscular use:

- **Cattle**
  - Milk. no withdrawal period zero days
  - Meat and offal. no withdrawal period zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI02AD01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Germany

Available in:
Germany

Package description:
Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (100 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (200 ml)
Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (10 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (20 ml)
Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (100 ml)

Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 PET vials of solvent (100 ml)
Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (5 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (10 ml)
Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (25 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (50 ml)
Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 glass vial (hydrolytic type II) of solvent (100 ml)
Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 PET vial of solvent (100 ml)
Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (5 doses) and 1 glass vial (hydrolytic type II) of solvent (10 ml)
Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (25 doses) and 1 glass vial (hydrolytic type II) of solvent (50 ml)
Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (100 doses) and 1 glass vial (hydrolytic type II) of solvent (200 ml)
Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (10 doses) and 1 glass vial (hydrolytic type II) of solvent (20 ml)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
Intervet Deutschland GmbH

Marketing authorisation date:
2/02/2012

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
PEI.V.11616.01.1

Date of authorisation status change:
2/02/2012

Reference member state:
Netherlands

Procedure number:
NL/V/0105/001

Concerned member states:
Austria Belgium France Germany Greece Ireland Italy Luxembourg Portugal Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.